News | February 28, 2026
Novartis completes $12 billion acquisition of Avidity Biosciences
The deal was executed via a merger of Novartis’ wholly owned subsidiary, Ajax Acquisition Sub, Inc., into Avidity
The deal was executed via a merger of Novartis’ wholly owned subsidiary, Ajax Acquisition Sub, Inc., into Avidity
The initiative, funded entirely under the company’s CSR programme, is expected to reach over a million lives
BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
Asahi Kasei is consistently pursuing its strategy of building a focused, sustainable specialty pharmaceutical platform for immunocompromised and medically complex patient groups
The innovative eyedrop targets inflammation and pain following ocular surgery
NCFB is a chronic lung condition where damaged airways cause persistent coughing and mucus production
The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands
Nadda underlined that India’s policy framework is aligned with this transformation
This partnership represents a systemic shift from awareness to large-scale action for 57 lakh children
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
Subscribe To Our Newsletter & Stay Updated
